Public Release:  Novel nanoparticle therapy promotes wound healing

Albert Einstein College of Medicine

IMAGE

IMAGE: Imaging of burns indicates that those treated with the FL2 inhibitor nanotechnology experienced collagen deposition and hair follicle formation. (2-photo confocal microscopy). view more

Credit: Vera DesMarais/Albert Einstein College of Medicine

March 26, 2015--(Bronx, NY)--An experimental therapy developed by researchers at Albert Einstein College of Medicine of Yeshiva University cut in half the time it takes to heal wounds compared to no treatment at all. Details of the therapy, which was successfully tested in mice, were published online in the Journal of Investigative Dermatology.

"We envision that our nanoparticle therapy could be used to speed the healing of all sorts of wounds, including everyday cuts and burns, surgical incisions, and chronic skin ulcers, which are a particular problem in the elderly and people with diabetes," said study co-leader David J. Sharp, Ph.D., professor of physiology & biophysics at Einstein.

Dr. Sharp and his colleagues had earlier discovered that an enzyme called fidgetin-like 2 (FL2) puts the brakes on skin cells as they migrate towards wounds to heal them. They reasoned that the healing cells could reach their destination faster if their levels of FL2 could be reduced. So they developed a drug that inactivates the gene that makes FL2 and then put the drug in tiny gel capsules called nanoparticles and applied the nanoparticles to wounds on mice. The treated wounds healed much faster than untreated wounds.

FL2 belongs to the fidgetin family of enzymes, which play varying roles in cellular development and function. To learn more about FL2's role in humans, Dr. Sharp suppressed FL2's activity in human cells in tissue culture. When those cells were placed on a standard wound assay (for measuring properties like cell migration and proliferation), they moved unusually fast. "This suggested that if we could find a way to target FL2 in humans, we might have a new way to promote wound healing," said Dr. Sharp.

Dr. Sharp and project co-leader Joshua Nosanchuk, M.D., professor of medicine at Einstein and attending physician, infectious diseases at Montefiore Medical Center, developed a wound-healing therapy that uses molecules of silencing RNA (siRNAs) specific for FL2. The siRNAs act to silence genes. They do so by binding to a gene's messenger RNA (mRNA), preventing the mRNA from being translated into proteins (in this case, the enzyme FL2). However, "siRNAs on their own won't be effectively taken up by cells, particularly inside a living organism" said Dr. Sharp. "They will be quickly degraded unless they are put into some kind of delivery vehicle."

To find a way to deliver siRNAs for curbing FL2, Dr. Sharp collaborated with Joel Friedman, M.D., Ph.D., professor of physiology & biophysics and of medicine at Einstein, and study co-leader Adam Friedman, M.D. director of dermatologic research at Einstein and Montefiore, who together had developed nanoparticles that protect molecules such as siRNA from being degraded as they ferry the molecules to their intended targets.

The nanoparticles with their siRNA cargoes were then tested by topically applying them to mice with either skin excisions or burns. In both cases, the wounds closed more than twice as fast as in untreated controls. "Not only did the cells move into the wounds faster, but they knew what to do when they got there," said Dr. Sharp. "We saw normal, well-orchestrated regeneration of tissue, including hair follicles and the skin's supportive collagen network."

Dr. Sharp plans to start testing the therapy on pigs, whose skin closely resembles that of humans, within months.

###

The paper, which published online March 10, is titled "Fidgetin-like 2: a novel microtubule-based regulator of wound healing." The other contributors, all at Einstein, are: Rabab Charafeddine, Ph.D. candidate; Joy Makdisi, M.D. student; David Schairer, M.D.; Brian O'Rourke, Ph.D..; Juan D. Diaz-Valencia, Ph.D.; Jason Chouake, M.D. student; Allison Kutner, M.D.; Aimee Krausz, M.D. student; Brandon Adler, M.D. student; Parimala Nacharaju, Ph.D.; Hongying Liang; Suranjana Mukherjee, Ph.D. candidate; and Joshua Nosanchuk, M.D.

VIDEO: http://youtu.be/n0szEQWrqoo

The research presented in this manuscript was funded by grants from the National Institute of Health (R01 GM109909) and the Telemedicine and Advanced Technology Research Center (TATRC) at the U.S. Army Medical Research and Materiel Command (USAMRMC) through award W81XWH1210379. Support was also granted by the Women's Dermatologic Society academic grant program.

David Sharp and Rabab Charafeddine are co-inventors on U.S. Patent #20130022667, "Fidgetin-like 2 as a target to enhance wound healing," which has been licensed by MicroCures Inc. Dr. Sharp is currently chief scientific officer of MicroCures. Dr. Sharp, Dr. Joel Friedman, Dr. Adam Friedman and Dr. Nosanchuk all have equity in the company. The other authors declare no conflicts of interest.

About Albert Einstein College of Medicine

Albert Einstein College of Medicine of Yeshiva University is one of the nation's premier centers for research, medical education and clinical investigation. During the 2013-2014 academic year, Einstein is home to 743 M.D. students, 275 Ph.D. students, 103 students in the combined M.D./Ph.D. program, and 313 postdoctoral research fellows. The College of Medicine has more than 2,000 full-time faculty members located on the main campus and at its clinical affiliates. In 2013, Einstein received more than $150 million in awards from the National Institutes of Health (NIH). This includes the funding of major research centers at Einstein in aging, intellectual development disorders, diabetes, cancer, clinical and translational research, liver disease, and AIDS. Other areas where the College of Medicine is concentrating its efforts include developmental brain research, neuroscience, cardiac disease, and initiatives to reduce and eliminate ethnic and racial health disparities. Its partnership with Montefiore Medical Center, the University Hospital and academic medical center for Einstein, advances clinical and translational research to accelerate the pace at which new discoveries become the treatments and therapies that benefit patients. Through its extensive affiliation network involving Montefiore, Jacobi Medical Center -- Einstein's founding hospital, and three other hospital systems in the Bronx, Brooklyn and on Long Island, Einstein runs one of the largest residency and fellowship training programs in the medical and dental professions in the United States. For more information, please visit www.einstein.yu.edu, read our blog, follow us on Twitter, like us on Facebook, and view us on YouTube.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.